Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06397781
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-11
First Post:
2024-04-30
Brief Title:
Effect of S Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Sponsor:
Boston Childrens Hospital
Organization:
Boston Childrens Hospital
Study Overview
Official Title:
Effect of S Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Our hypothesis is that S aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity
Detailed Description:
Patients will sign an informed consent and assent to participate Skin and both nares will be cultured for S aureus A blood sample and two 2 mm skin biopsies will be obtained one from non-lesional skin and another one from lesional skin The patients will be instructed in the use of the three-week S aureus decolonization regimen and provided with the medications sulfamethoxazoletrimethoprim and Mupirocin ointment and Chlorhexidine The second visit will take place immediately at the end of the three-week S aureus skin decolonization regimen Disease severity will be assessed the skin and nares will be re-cultured and skin biopsies and blood will be obtained
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None